Tabaco y enfermedad arterial no coronaria. Intervenciones para el abandono del hábito tabáquico

Banegas Banegas, 2001, Mortalidad atribuible al tabaquismo en España en 1998, Med Clin (Barc), 117, 692, 10.1016/S0025-7753(01)72226-9 Ambrose, 2004, The pathophisiology of cigarette smoking and cardiovascular disease, J Am Coll Cardiol, 43, 1731, 10.1016/j.jacc.2003.12.047 Fageström, 2002, The epidemiology of smoking; health consequences and benefits of cessation, Drugs, 62, 1 2000, Transatlantic Intersociety Consensus (TASC), J Vasc Surg, 31, S1 Erb, 1911, Klinische Beitrage zur Pathologie des Intermittierenden Hinkens, Munch Med Wochenschr, 2, 2487 Willigendael, 2004, Influence of smoking on incidence and prevalence of peripheral arterial disease, J Vasc Surg, 40, 1158, 10.1016/j.jvs.2004.08.049 Fiore, 2000, Treating tobacco use and dependence. Clinical Practice Guideline. Rockville: US Department of Health and Human Services, Public Health Service Tonnesen, 2007, Task Force recommendations smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy, Eur Respir J, 29, 390, 10.1183/09031936.00060806 Akehurst RL, Bernett D, Berry C, Bird S, Buxton M, Claxton K, et al. Guidance on the use of nicotine replacement therapy and bupropion for smoking cessation. National Institute for Clinical Excellence. Disponible en: www.nice.org.uk Khosla, 1994, Cardiovascular effects of nicotine: Relation to deleterious effects of cigarette smoking, Am Heart J, 127, 1669, 10.1016/0002-8703(94)90423-5 Craig, 1989, Cigarette smoking and serum lipid and lipoprotein concentration; an analysis of published data, BMJ, 298, 784, 10.1136/bmj.298.6676.784 Yarnell, 1991, Fibrinogen, viscosity and white blood cell count are major risk factors for ischemic heart disease. The Caerphilly and Speedwell Collaborative Heart Disease Studies, Circulation, 83, 836, 10.1161/01.CIR.83.3.836 Lee, 1996, Haemostatic and rheological factors in intermittent claudication: the influence of smoking and extent of arterial disease, Br J Haematol, 92, 226, 10.1046/j.1365-2141.1996.00283.x Kool, 1993, Short and long term effects of smoking on arterial wall properties in habitual smokers, J Am Coll Cardiol, 22, 1881, 10.1016/0735-1097(93)90773-T Rahman, 2008, Neuronal nicotinic receptors as brain targets for pharmacotherapy of drug addiction, CNS Neurol Disord Drug Targets, 7, 422, 10.2174/187152708786927831 Fowler, 2008, Subtypes of nicotinic acetylcholine receptors in nicotine reward, dependence, and withdrawal: Evidence from genetically modified mice, Behav Pharmacol, 19, 461, 10.1097/FBP.0b013e32830c360e Walsh, 2008, Up-regulation of nicotinic receptors by nicotine varies with receptor subtype, J Biol Chem, 283, 6022, 10.1074/jbc.M703432200 Volkow, 2004, Drug addiction: the neurobiology of behaviour gone away, Nat Rev Neurosci, 5, 963, 10.1038/nrn1539 World Health Organization. Tobacco Free Initiative. Report by the Director-General. Executive Board EB 103/5. Provisional agenda item 3. 103rd Session 8 December 1998. Prochaska, 1983, Stages and Processes of self changes in smoking: towards an integrative model of change, J Consult Clin Psychol, 51, 390, 10.1037/0022-006X.51.3.390 Ramos, 2004, Estudio clínico y diagnóstico del fumador, Vol. 7, 87 Richmond, 1993, Multivariate models for predicting abstention following intervention to stop smoking by general practitioner, Addiction, 88, 1127, 10.1111/j.1360-0443.1993.tb02132.x Glover, 2005, Developmental history of the Glover-Nilsson smoking behavioural questionnaire, Am J Health Behav, 29, 443, 10.5993/AJHB.29.5.7 Fagerström, 1989, Measuring nicotine dependence: a review of the Fagerström Tolerance Questionnaire, J Behav Med, 12, 159, 10.1007/BF00846549 1996, The smoking cessation clinical practice guideline, JAMA, 275, 1270, 10.1001/jama.1996.03530400058039 2008 Jiménez Ruiz, 1998, Terapia sustitutiva con nicotina. Aspectos prácticos, Rev Clin Esp, 198, 1599 Fagerström, 2004, Tratamiento farmacológico del tabaquismo, 101 Shiffman, 2003, Efficacy of acute administration of nicotine gum in relief of cue-provoked cigarette craving, Psicopharmacology, 166, 343, 10.1007/s00213-002-1338-1 Shiffman, 2005, Nicotine delivery systems, Expert Opin Drug Deliv, 2, 563, 10.1517/17425247.2.3.563 Tonnesen, 1999, Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE-trial, Eur Respir, 13, 238, 10.1034/j.1399-3003.1999.13b04.x Hurt, 1997, A comparison of sustained release Bupropion and placebo for smoking cessation, N Engl J Med, 337, 1195, 10.1056/NEJM199710233371703 Wu, 2006, Effectiveness of smoking cessation therapies: a systematic review and metaanalysis, BMC Public Health, 6, 300, 10.1186/1471-2458-6-300 Benowitz, 2004, Pharmacotherapy for smoking cessation during pregnancy, Nicotine Tob Res, 6, S189, 10.1080/14622200410001669169 Nakamura, 2007, Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers, Clin Ther, 29, 1040, 10.1016/j.clinthera.2007.06.012 Aubin, 2008, Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomized open-label trial, Thorax, 63, 717, 10.1136/thx.2007.090647 Jorenby, 2006, Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs. placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial, JAMA, 296, 56, 10.1001/jama.296.1.56 Gonzales, 2006, Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs. sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial, JAMA, 296, 47, 10.1001/jama.296.1.47 Tavares, 2009, Varenicline for tobacco dependence, N Engl J Med, 360, 731 Food and Drug Administration. Public health advisory: important information on Chantix (varenicline) [citado 23 Ene 2009]. Disponible en: http://www.fda.gov/cder/drug/advisory/varenicline.htm Cantrell, 2009, Varenicline for tobacco dependence, N Engl J Med, 360, 730, 10.1056/NEJMc082464 Hays, 2008, Varenicline for tobacco dependence, N Engl J Med, 359, 2018, 10.1056/NEJMct0800146 Volpp, 2009, A randomized, controlled trial of financial incentives for smoking cessation, N Engl J Med, 360, 699, 10.1056/NEJMsa0806819 Kotseva, 2009, Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries, Lancet, 373, 929, 10.1016/S0140-6736(09)60330-5 2009, Lancet, 373, 867, 10.1016/S0140-6736(09)60518-3